This segment focuses on the research, development, and commercialization of long-acting anti-infectives to treat and prevent infectious diseases. The primary focus is on rezafungin, an echinocandin antifungal for invasive fungal infections like candidemia and invasive candidiasis, which are associated with high mortality rates. Research and development activities include clinical trials to evaluate the efficacy and safety of rezafungin. The company utilizes advanced technologies and methodologies in drug discovery and development, including formulation science and clinical trial design. The patient impact is significant, as rezafungin aims to improve outcomes for patients with life-threatening fungal infections. Market positioning involves competing with existing antifungal therapies while offering a potentially improved treatment option. Future opportunities include expanding the use of rezafungin and developing new anti-infective agents. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations may be pursued to support clinical development and commercialization efforts.

This segment centers on Cidara's proprietary Cloudbreak platform, which is used to develop drug-Fc conjugate (DFC) immunotherapies. The research and development activities involve creating DFCs for the prevention and treatment of viral infections, including influenza, RSV, HIV, and SARS-CoV-2 strains. The technology utilizes the Fc portion of an antibody to extend the half-life of the drug and enhance its therapeutic effect. This segment focuses on developing novel immunotherapies with improved efficacy and duration of action. The therapeutic areas covered include infectious diseases and potentially oncology. The patient impact is aimed at providing more effective and convenient treatment options for viral infections. Market positioning involves differentiating from traditional antiviral therapies by offering long-acting immunotherapies. Future opportunities include expanding the DFC pipeline to address additional viral threats and exploring applications in oncology. Regulatory and clinical aspects involve conducting clinical trials to demonstrate the safety and efficacy of DFCs. Partnerships and collaborations are essential for advancing the development and commercialization of DFCs.